[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ondansetron\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ondansetron":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,83,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100649737","phase-4-routine-antiemetic-prophylaxis-for-nonfasted-parturients-undergoing-cesarean-sections-under-spinal-anesthesia-100649737",false,"NCT07740577","Routine Antiemetic Prophylaxis for Nonfasted Parturients Undergoing Cesarean Sections Under Spinal Anesthesia","Comparative Effectiveness of Routine Antiemetic Prophylaxis in Nonfasted Parturients Undergoing Cesarean Sections Under Spinal Anesthesia: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women scheduled for emergency cesarean delivery under spinal anesthesia\n* Non-fasted (full-stomach) parturients\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Age ≥ 18 years\n* Singleton pregnancy\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* ASA physical status III or higher\n* Refusal to participate\n* Elective cesarean delivery (non-emergency cases)\n* Preoperative antiemetic use within 24 hours before surgery\n* Known allergy or contraindication to study drugs (ondansetron or metoclopramide)\n* Pre-existing gastrointestinal disorders (e.g., severe GERD, gastroparesis, bowel obstruction)\n* Psychiatric illness or current use of psychotropic medications\n* Preoperative anemia (as defined by institutional threshold, e.g., Hb \\\u003C 10 g\u002FdL)\n* Intraoperative conversion to general anesthesia\n* Massive intraoperative hemorrhage (\\>1000-1500 mL or requiring transfusion, depending on your protocol definition)\n* Intraoperative administration of additional sedative or antiemetic agents outside study protocol\n* Multiple gestation pregnancies","FEMALE","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The aim of this prospective randomized double-blind study is to compare the effectiveness of routine antiemetic prophylaxis for the prevention of intraoperative nausea and vomiting (IONV) in non-fasted parturients undergoing emergency cesarean section under spinal anesthesia.\n\nNausea and vomiting are common complications during cesarean delivery performed under spinal anesthesia and may negatively affect maternal comfort and perioperative safety. The incidence of these symptoms may be particularly increased in emergency cesarean sections involving non-fasted (full-stomach) parturients. This study compares two commonly used antiemetic strategies, namely 5-hydroxytryptamine-3 (5-HT3) receptor antagonists and dopamine receptor antagonists, to determine their relative effectiveness in preventing IONV during surgery.\n\nThe findings are expected to contribute to optimization of antiemetic prophylaxis protocols, improvement of maternal comfort, and reduction of perioperative complications associated with nausea and vomiting during emergency cesarean delivery.",[26,27,28,29,30,31],"Intraoperative Nausea-retching-vomiting Episodes","Spinal Aneshtesia","Ceserean Section","Antiemetic Therapy","Ondansetron","Metoclopramide",[33,34,35,36,37,38,39,40,41],"Cesarean Section","Emergency Cesarean Delivery","Non-fasted Parturients","Full Stomach","Spinal Anesthesia","Antiemetic Prophylaxis","Intraoperative Nausea and Vomiting","Obstetric Anesthesia","Maternal Outcomes","RECRUITING","2026-08-16",{"date":45,"type":46},"2026-08-18","ACTUAL",{"date":48,"type":46},"2026-07-30",{"date":50,"type":20},"2027-01-02",{"name":52,"class":53},"Sanliurfa Education and Research Hospital","OTHER_GOV",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269","NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","40 Years",{"count":64,"type":20},90,[66],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[30,69,70,71,72,33],"Lozenge","Intravenous","Prevention","Shivering","2026-06-22",{"date":75,"type":46},"2026-06-23",{"date":77,"type":46},"2026-04-11",{"date":79,"type":20},"2026-08-30",{"name":81,"class":82},"Tanta University","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":54},"100578406","intravenous-versus-perineural-ondansetron-for-laparoscopic-sleeve-gastrectomy-100578406","NCT06810882","Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy","Intravenous Versus Perineural Ondansetron as an Adjuvant in Autonomic Neural Blockade for Laparoscopic Sleeve Gastrectomy: A Two-Center, Randomized, Double-Blind, Non-inferiority Trial","Inclusion Criteria:\n\n* Patients of either sex\n* American Society Anesthesiologists physical (ASA) status II-III\n* age between 18-65 years old\n* Body mass index (BMI) \\>35 kg\u002Fm2 with comorbidity or \\> 40 kg\u002Fm2 -- undergoing laparoscopic sleeve gastrectomy with intraoperative surgeon performed laparoscopic paragastric autonomic neural blockade..\n\nExclusion Criteria:\n\n* Allergy to experimental drugs.\n* Known to have long QT, previous history of postoperative nausea and vomiting\n* Abuse of alcohol, analgesia, or sedative antidepressant drugs\n* Chronic pain disorders\n* History of previous upper gastrointestinal system surgery, those with surgery-related complications during or after surgery.\n* Liver or kidney failure\n* Performance of concomitant procedures in addition to laparoscopic sleeve gastrectomy\n* Anesthetic complications that may alter the postoperative management protocol.","ALL","65 Years",{"count":93,"type":20},482,[66],"This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.",[30,97,98],"Laparoscopic","Gastrectomy",[30,97,98],"2026-05-13",{"date":102,"type":46},"2026-05-15",{"date":104,"type":46},"2025-02-16",{"date":106,"type":20},"2027-02-17",{"name":81,"class":82},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":90,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":54},"100630597","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-tonsillectomy-100630597","NCT07489742","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Children undergoing tonsillectomy under general anesthesia.\n\nExclusion Criteria:\n\n* Allergy to ondansetron.\n* History of sleep apnea.\n* Cardiac and respiratory diseases.\n* Upper respiratory tract infection.\n* Taking corticosteroids.","4 Years","15 Years",{"count":118,"type":20},210,[66],"This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in tonsillectomy.",[30,69,70,72,122],"Tonsillectomy","2026-03-25",{"date":125,"type":46},"2026-03-27",{"date":123,"type":46},{"date":128,"type":20},"2026-09-01",{"name":81,"class":82}]